Summary of findings 1: Efficacy and safety of IVT lampalizumab 4‐weekly (monthly) vs shamQoL · adults with GA due to AMD1 finding from 1 reviewComplement inhibitors for age‐related macular degeneration 2023 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 983 participantsHigh